In today's episode, Megan provides a step-by-step update on her compounded semaglutide journey. She and Harini also contemplate the quick but quiet death of the Ozempic craze (at least by frenzied-netizen-discourse standards). Why were we all so passionately opiniated about Ozempic for five months, and now can barely get DailyMail to cover it? And what has the FDA had to say since the Ozempic name has become passé? Tune in to find out!
NOTE: Since the recording of this episode, the American Diabetes Association has released new data on a wide-array of novel GLP-1 agonists ("obesity drugs") that truly make semaglutide old news. Read about it here: https://www.theatlantic.com/health/archive/2023/06/ozempic-pills-obesity-drugs-semaglutide/674541/See omnystudio.com/listener for privacy information.